<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7228359\results\search\testTrace\results.xml">
  <result pre="elaborates on the idea of considering AT1R blockers as tentative" exact="treatment" post="for SARSâ€�CoVâ€�2 infections, and proposes a research direction based"/>
  <result pre="2020). Yet, no SARSâ€�CoVâ€�2 therapeutics are presently available, albeit some" exact="treatment" post="options which await validation have been published, including several"/>
  <result pre="system is dysregulated by SARSâ€�CoVâ€�2. A similar suggestion proposing the" exact="treatment" post="of COVIDâ€�19 patients with AT1R blockers was put forward"/>
  <result pre="shown to increase cardiac ACE2 expression about threeâ€�fold following chronic" exact="treatment" post="(28â€‰days) after myocardial infarction induced by coronary artery ligation"/>
  <result pre="patients who were prescribed with AT1R antagonists prior to their" exact="diagnosis" post="(for treating their hypertension, diabetic kidney disease, or other"/>
  <result pre="X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVIDâ€�19 associated pneumonia in clinical studies. Bioscience Trends."/>
 </snippets>
</snippetsTree>
